Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535415 | 0.87 | NR1I2 (0.35) | OPRK1NR1I2KDM4ENPC1ALDH1A1 | |
| SCHEMBL17535322 | 0.81 | HIF1A (0.40) | KDM4EALDH1A1MAPT | |
| SCHEMBL16055145 | 0.77 | RAB9A (0.49) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL30783797 | 0.75 | SCD (0.39) | MAPT | |
| SCHEMBL1665317 | 0.73 | NPC1 (0.49) | KDM4ENPC1ALDH1A1MAPTHPGD | |
| SCHEMBL17535813 | 0.73 | WHR1 (0.38) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL30783763 | 0.71 | SCD (0.36) | ALDH1A1MAPT | |
| SCHEMBL30762524 | 0.71 | SCD (0.39) | — | |
| SCHEMBL30783866 | 0.71 | TSHR (0.36) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL16055167 | 0.70 | MAPT (0.32) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | OPRK1 1046/4885NR1I2 1533/4885KDM4E 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.